WO2019220448A1 - Composition pharmaceutique pour le traitement de l'allergie - Google Patents

Composition pharmaceutique pour le traitement de l'allergie Download PDF

Info

Publication number
WO2019220448A1
WO2019220448A1 PCT/IN2018/000036 IN2018000036W WO2019220448A1 WO 2019220448 A1 WO2019220448 A1 WO 2019220448A1 IN 2018000036 W IN2018000036 W IN 2018000036W WO 2019220448 A1 WO2019220448 A1 WO 2019220448A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
gms
allergy
allergic
secretion
Prior art date
Application number
PCT/IN2018/000036
Other languages
English (en)
Inventor
Kalyan PASUPATHI
Original Assignee
Pasupathi Kalyan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasupathi Kalyan filed Critical Pasupathi Kalyan
Publication of WO2019220448A1 publication Critical patent/WO2019220448A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/264—Aristolochia (Dutchman's pipe)

Definitions

  • the present invention relates to a pharmaceutical formulation. More particularly the present invention relates to an anti-allergic pharmaceutical composition for treatment of allergy in fast track recovery thereby correcting immunological abnormalities, TH 1 / TH2 secretion, lymphocytes, skin rashes, regularizing path physiological functions and normalizing vasodilatation mucous secretion, nerve, stimulation, and smoothen the muscle contraction.
  • Allergies also known as allergic diseases, are a number of conditions caused by hypersensitivity of the immune system to something in the environment that usually causes little or no problem in most people. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis. Symptoms may include red eyes, an itchy rash, sneezing, a runny nose, shortness of breath, or swelling. Food intolerances and food poisoning are separate conditions. Common allergens include pollen and certain food. Metals and other substances may also cause problems. Food, insect stings, and medications are common causes of severe reactions. Their development is due to both genetic and environmental factors. The underlying mechanism involves immunoglobulin E antibodies (IgE), part of the body's immune system, binding to an allergen and then to a receptor on mast cells or basophils where it triggers the release of inflammatory chemicals such as histamine.
  • IgE immunoglobulin E antibodies
  • US 5122372 discloses a process for treating allergies by administering to a mammal a pharmaceutically effective amount of gamma interferon.
  • US 6369032 discloses use of cathepsin S inhibitors for the treatment of an allergic condition, in particular an atopic allergic condition, more specifically for the treatment of hay fever, asthma, atopic dermatitis or a food allergy.
  • US 721 1567 disclose a method for treating type I allergy human pollinosis in a subject, comprising: administering kaempferol-3-glucoside in an effective amount to a subject who suffers from pollinosis.
  • US 7687539 discloses topical use of 5,6,7-trihydroxyheptanoic acid and analogs alone or in combination with histamine antagonists and/or mast cell stabilizers for the treatment of ocular allergy.
  • US 9095603 discloses a method for treatment of an allergy, comprising of administering to a subject a pharmaceutical composition comprising an anti-allergy agent consisting of oxidized cellulose.
  • US 7344739 discloses a herbal anti-allergy formulation comprising a mixture of juice or extract of (a) Tinospora cordifolia (2-3 wt %), (b) Piper longum (0.5-2 wt %), (c) Albizzia lebbeck (3-5 wt %), (d) Curcuma amada (3-5 wt %), and (e) balance comprising one or more pharmaceutically acceptable additives.
  • US 7384656 discloses a method for inhibiting an allergic response in a human subject comprising orally administering to the human subject an effective amount of a composition including a Cinnamon ingredient in an amount of about 25 mg to about 650 mg, an Acerola ingredient in an amount of about 25 mg to about 650 mg, and a Picao preto ingredient in an amount of about 25 mg to about 650 mg, wherein the ingredients operate to at least one of down- regulate IgE expression, inhibit lgE secretion and inhibit an allergy mediator.
  • the main object of the present invention is to develop a novel pharmaceutical formulation for treating allergy in fast track recovery.
  • Another object of the present invention is to develop a pharmaceutical formulation comprising of senna indica and castor oil and optionally comprises of silasithu (Purified Herbally coated Asbhaltum or Alum of Nepal burnt with 6000°C + Terminalia chebula), and Aristolochia Bacteata.
  • Yet another object of the present invention is to develop a pharmaceutical formulation for treating all types of allergies.
  • Yet another object of the present invention is to develop a pharmaceutical formulation with double strength, which can treat allergies even in advanced stage rapidly.
  • Further object of the present invention is to develop a novel pharmaceutical formulation for treating allergy by correcting immunological abnormalities, TH 1 / TH2 secretion, lymphocytes, skin rashes, regularizing path physiological functions and normalizing vasodilatation mucous secretion, nerve, stimulation, and smoothen the muscle contraction.
  • the present invention shall disclose an anti-allergic pharmaceutical composition for treatment of allergy in fast track recovery thereby correcting immunological abnormalities, TH 1 / TH2 secretion, lymphocytes, skin rashes, regularizing path physiological functions and normalizing vasodilatation mucous secretion, nerve, stimulation, and smoothen the muscle contraction.
  • the pharmaceutical composition comprises of combination of therapeutically effective amounts of Senna lndica and Castor oil along with pharmaceutically acceptable additives and optionally comprises of si!asithu(Purified Herbally coated Asbhaltum or Alum of Nepal burnt with 6000°C + Terminalia chebula), and Aristolochia Bacteata.
  • the present invention relates to an anti-allergic pharmaceutical composition for treatment of an allergy in fast track recovery.
  • the composition of the present invention comprises of senna indica and castor oil and optionally comprises of silasithu (Purified Herb ally coated Asbhaltum or Alum of Nepal burnt with 6000°C + Terminalia chebula), and Aristolochia Bacteata.
  • All allergies related to hereditary, sex, age, race and environmental related and even food, pollution and life style related allergy can also be control with composition of the present invention. Allergy rhinitis, asthma, atopic eczyma, anaphylaxis insect venom, drug allergies, itchiness, dysnea and all other types of also.
  • composition of the present invention is next subjected to clinical trials to establish the efficacy.
  • the composition of the present invention is daily administered to human subjects and various studies were conducted to study the efficacy of the composition.
  • the composition of the present invention upon administration of the composition of the present invention, it reduces lgE level up to normalization of below 200 which in turn normalizes the WBC count to 8000. Further it reduces neutrophiles to normal level of 65 which in turn normalizes the lymphocytes to normal level of less than 35 and boost monocytes from 8% to 3 % Moreover the allergy is cured within maximum of 20 days.
  • the formulation of the present invention corrects immunological abnormalities, TH I / TH2 secretion, lymphocytes, skin rashes, regularizing path physiological functions and normalizing vasodilatation mucous secretion, nerve, stimulation, and smoothen the muscle contraction. Further it is reiterated that the composition of the present invention is free from any side effects.
  • the composition of the present invention upon administration of the composition of the present invention, it reduces lgE level up to normalization of below 200 which in turn normalizes the WBC count to 8000. Further it reduces neutrophiles to normal level of 65 which in turn normalizes the lymphocytes to normal level of less than 35 and boost monocytes from 8% to 3 % . Moreover the allergy is cured within maximum of 20 days.
  • the formulation of the present invention corrects immunological abnormalities, TH I / TH2 secretion, lymphocytes, skin rashes, regularizing path physiological functions and normalizing vasodilatation mucous secretion, nerve, stimulation, and smoothen the muscle contraction. Further it is reiterated that the composition of the present invention is free from any side effects.
  • the present invention shall disclose an anti-allergic pharmaceutical composition for treatment of an allergyin fast track recovery thereby correcting immunological abnormalities, TH1 / TH2 secretion, lymphocytes, skin rashes, regularizing path physiological functions and normalizing vasodilatation mucous secretion, nerve, stimulation, and smoothen the muscle contraction.
  • the pharmaceutical composition comprises of combination of therapeutically effective amounts of Senna Indica and Castor oil along with pharmaceutically acceptable additives and optionally comprises of therapeutically effective amounts of silasithu (Purified Herbally coated Asbhaltum or Alum of Nepal burnt with 6000°C with Terminalia chebula), and Aristolochia Bacteata.
  • the present invention shall disclose an anti-allergic pharmaceutical composition for treatment of an allergy in fast track recovery thereby correcting immunological abnormalities, TH 1 / TH2 secretion, lymphocytes, skin rashes, regularizing path physiological functions and normalizing vasodilatation mucous secretion, nerve, stimulation, and smoothen the muscle contraction.
  • the pharmaceutical composition comprises of combination of 1 gm to 4.5 gms of Senna Indica and 8mL to 10 mL of Castor oil along with pharmaceutically acceptable additives and optionally comprises of silasithu (Purified Herbally coated 8 gms to 12 gms of Asbhaltum or Alum of Nepal burnt with 6000°C + 3gms to 7 gms of Terminalia chebula), and 3gms to 5 gms of Aristolochia Bacteata.
  • silasithu Purified Herbally coated 8 gms to 12 gms of Asbhaltum or Alum of Nepal burnt with 6000°C + 3gms to 7 gms of Terminalia chebula
  • the present invention shall disclose an anti-allergic pharmaceutical composition for treatment of an allergy in fast track recovery thereby correcting immunological abnormalities, TH 1 / TH2 secretion, lymphocytes, skin rashes, regularizing path physiological functions and normalizing vasodilatation mucous secretion, nerve, stimulation, and smoothen the muscle contraction.
  • the pharmaceutical composition comprises of combination of 3.5gms to 4.5 gms of Senna Indica, 10 mL of Castor oil, si!asithu (Purified Herbally coated 10 gms of Asbhaltum or Alum of Nepal burnt with 6000°C + 5 gms of Terminalia chebula), along with pharmaceutically acceptable additives in which the formulation is suitable for treating early stage of allergy.
  • the present invention shall disclose a double strength antiallergic pharmaceutical composition for treatment of an allergy in fast track recovery thereby correcting immunological abnormalities, TH I / TH2 secretion, lymphocytes, skin rashes, regularizing path physiological functions and normalizing vasodilatation mucous secretion, nerve, stimulation, and smoothen the muscle contraction.
  • the pharmaceutical composition comprises of combination of lgm of Senna Indica, 10 mL of Castor oil, silasithu (Purified Herbally coated 10 gms of Asbhaltum or Alum of Nepal burnt with 6000°C + 5 gms of Terminalia chebula), and 4 gms of Arislochia Bracteata along with pharmaceutically acceptable additives in which the formulation is suitable for treating advanced stage of allergy.
  • the Senna Indica, Terminalia chebula, and Aristolochia Bacteata are cleansed, dried and powdered whole Senna Indica plant, Terminalia chebula plant, and Aristolochia Bacteata plant respectively.
  • the anti-allergic pharmaceutical composition can be formulated in to form selected from the group consisting of an injection, a pediatric suspension, capsules or tablet and the like.
  • the dosage of the anti-allergic pharmaceutical composition is 3.5gms for 3-times a day after food.
  • the anti-allergic pharmaceutical composition upon administration for treating allergy reduces IgE level up to normalization of below 200 which in turn normalizes the WBC count to 8000.
  • the anti-allergic pharmaceutical composition upon administration for treating allergy reduces neutrophiles to normal level of 65 which in turn normalizes the lymphocytes to normal level of less than 35 and boost monocytes from 8 level to 3 %
  • the allergy is selected from the group comprising of Allergic rhinitis, Asthma, Atopic eczema, Anaphylaxis, Insect venom, Drug allergies, Food allergies, rhino rhea itchiness, dysnea and Multiple allergies (Asthma, eczema and allergic rhinitis together).

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique antiallergique pour le traitement d'une allergie dans une récupération de voie rapide, ce qui permet de corriger des anomalies immunologiques, une sécrétion de TH1/TH2, les lymphocytes, les éruptions cutanées, les fonctions physiologiques du trajet de régularisation et la normalisation de la sécrétion des muqueuses par la vasodilatation, du nerf, de la stimulation et du lissage de la contraction musculaire. La composition pharmaceutique comprend une combinaison de quantités thérapeutiquement efficaces de Senna Indica et d'huile de ricin conjointement avec des additifs pharmaceutiquement acceptables et comprend éventuellement des silasithu (Asbhaltum ou Alun revêtu herbalement purifié de népal brûlé avec 6000 °C + Terminalia chebula), et Aristolochia Bacteata.
PCT/IN2018/000036 2018-05-17 2018-06-29 Composition pharmaceutique pour le traitement de l'allergie WO2019220448A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841018516 2018-05-17
IN201841018516 2018-05-17

Publications (1)

Publication Number Publication Date
WO2019220448A1 true WO2019220448A1 (fr) 2019-11-21

Family

ID=68539651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2018/000036 WO2019220448A1 (fr) 2018-05-17 2018-06-29 Composition pharmaceutique pour le traitement de l'allergie

Country Status (1)

Country Link
WO (1) WO2019220448A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117379420A (zh) * 2023-12-12 2024-01-12 中国中医科学院中药研究所 马兜铃内酰胺bii在制备升白细胞产品中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194452A1 (en) * 2000-02-28 2003-10-16 Agarwal Ravindra Kumar Improved herbal composition having antiallergic properties and a process for the preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194452A1 (en) * 2000-02-28 2003-10-16 Agarwal Ravindra Kumar Improved herbal composition having antiallergic properties and a process for the preparation thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHITME HR ET AL.: "Antiallergic activity of Aristolochia bracteolata Lank in animal model", INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol. 48, no. 1, January 2010 (2010-01-01), pages 46 - 52, XP055653469 *
KISHOR PANT ET AL.: "Shilajit: A Humic Matter Panacea for Cancer", INTERNATIONAL JOURNAL OF TOXICOLOGICAL AND PHARMACOLOGICAL RESEARCH, vol. 4, no. 2, August 2012 (2012-08-01), pages 17 - 25, XP055653464 *
MEGHENDRA SHARMA ET AL.: "Pharmacognostial Characterization of Some Selected Medicinal Plants of Semi-Arid Regions", JOURNAL OF PHARMACOGNOSY AND PHYTOCHEMISTRY, vol. 1, no. 6, 2013, pages 216 - 228, XP055653457 *
SHIVJEET SINGH ET AL.: "A Review on Cassia species: Pharmacological, Traditional and Medicinal Aspects in Various Countries", AMERICAN JOURNAL OF PHYTOMEDICINE AND CLINICAL THERAPEUTICS, vol. 1, no. 3, 2013, pages 291 - 312, XP055653438 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117379420A (zh) * 2023-12-12 2024-01-12 中国中医科学院中药研究所 马兜铃内酰胺bii在制备升白细胞产品中的用途
CN117379420B (zh) * 2023-12-12 2024-02-13 中国中医科学院中药研究所 马兜铃内酰胺bii在制备升白细胞产品中的用途

Similar Documents

Publication Publication Date Title
JPWO2003088988A1 (ja) 花粉症、アレルギー性鼻炎、アトピー性皮膚炎、喘息又は蕁麻疹の予防又は治療用組成物
US9993512B2 (en) Use of escin
KR100671432B1 (ko) 천식의 유지치료용 약제
AU2014249456A1 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
TWI740051B (zh) 用於治療中風及減少神經損傷的化合物及其用途
Farokhi et al. Histophatologic changes of lung in asthmatic male rats treated with hydro-alcoholic extract of Plantago major and theophylline
WO2019220448A1 (fr) Composition pharmaceutique pour le traitement de l'allergie
Gehanno et al. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis
JP2000512270A (ja) 単純ヘルペスの処置のための組成物および方法
US20140234306A1 (en) Agent and Method for Reducing Inflammatory Markers
Hotsulia et al. Experimental simulation of tuberculosis and its features in rabbits under conditions of isoniazid and N'-(2-(5-((theophyline-7-yl) methyl)-4-ethyl)-1, 2, 4-triazole-3-ylthio) acetyl) isonicotinohydrozide
JP5435608B2 (ja) 霊芝エキスを有効成分とする哺乳動物における３型ヘルパーＴ細胞からのＴＧＦ−β産生抑制剤
Agah et al. Chamomile efficacy in patients of the irritable bowel syndrome
US20040198696A1 (en) Agent and food for inhibiting IgE antibody
JP2007517829A (ja) 植物抽出組成物
DE60028243T2 (de) Asthma- und allergiebehandlung die auf t-lymphozyten und/oder eosinophile ausgerichtet ist
Shreelakshmi et al. A clinical study to evaluate the efficacy of haridrakhanda in the management of allergic rhinitis in paediatric age group
WO2023214819A1 (fr) Composition pour la prévention ou le traitement du psoriasis comprenant un extrait de feuille d'isatis
JP4797326B2 (ja) 生薬含有組成物
TWI679986B (zh) 鈴蘭精油之應用
kumar Das et al. The efficacy of an Ayurvedic polyherbal formulation in the symptomatic management of mild COVID-19 cases: A double blind, randomized controlled trial
Singh et al. A Clinico-Pathological Study On Eosinophilic Patients And Its Management With Haridra Khanda And Shirishadi Yoga
Oduyemi et al. Comparative Effects of Phyllantus Amarus on the Serum Electrolyte Level of Hypertensive and Normotensive Male Wistar Rats
Eniyaranjani Evaluation of Anti asthmatic activity of Siddha formulation, Kaagamasi thailam in eosinophilia and mast cell degranulation induced mice models
Li et al. Clinical study of Loratadine Tablet combined with Mometasone Furoate nasal spray combined with acupoint application of traditional Chinese Medicine in the treatment of allergic Rhinitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18919253

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18919253

Country of ref document: EP

Kind code of ref document: A1